Episode
Non-Small Cell Lung Cancer — 5-Minute Journal Club Issue 2 with Dr Jacob Sands: Defining the Role of TROP2-Directed Antibody-Drug Conjugates
- Podcast
- Lung Cancer Update
- Published
- Sep 14, 2025
- Duration seconds
- 1399
- Processing state
not_requested
Actions
POST https://stenobird.com/v1/public/podcasts/lung-cancer-update-827388/episodes/non-small-cell-lung-cancer-5-minute-journal-club-issue-2-with-dr-jacob-sands-defining-the-role-of-trop2-directed-antibody-drug-conjugates/transcription-requests
Idempotently request low-priority transcript generation for this episode.GET https://stenobird.com/podcast/lung-cancer-update-827388/non-small-cell-lung-cancer-5-minute-journal-club-issue-2-with-dr-jacob-sands-defining-the-role-of-trop2-directed-antibody-drug-conjugates.md
Read the agent-friendly Markdown representation of this episode resource.
Summary
Dr Jacob Sands from Dana-Farber Cancer Institute in Boston, Massachusetts, discusses recent developments with TROP2-directed antibody-drug conjugates in the management of lung cancer. CME information and select publications here .